Clinical Trial Update: Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study [Phase 1]

View source ↗

Summary

Phase 1 first-in-human safety, tolerability, and pharmacokinetics study (TAK-041) in schizophrenia and healthy volunteers completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• TAK-041 (TAK-041)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Healthy Volunteers, Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2021-03-01